Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667108 · ClinicalTrials.gov registry record · Phase 3
A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 784
- Enrollment target
NCT00667108 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 784 participants.
The verdict
NCT00667108, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 784 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
Interventions
- DRUG Placebo
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667108
The ClinicalTrials.gov registry entry for NCT00667108 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 784 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00667108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667108 about?
NCT00667108 is a clinical study titled "A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance". The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
What is the current status of trial NCT00667108?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 784 participants. The study started on 2004-10. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00667108?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00667108?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.